A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...
Please provide your email address to receive an email when new articles are posted on . Current recommendations suggest withholding long-acting beta-agonists prior to an OFC. OFC reaction severity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results